MX2017001012A - Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo. - Google Patents

Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo.

Info

Publication number
MX2017001012A
MX2017001012A MX2017001012A MX2017001012A MX2017001012A MX 2017001012 A MX2017001012 A MX 2017001012A MX 2017001012 A MX2017001012 A MX 2017001012A MX 2017001012 A MX2017001012 A MX 2017001012A MX 2017001012 A MX2017001012 A MX 2017001012A
Authority
MX
Mexico
Prior art keywords
antibody
relates
present
cytosol
chain variable
Prior art date
Application number
MX2017001012A
Other languages
English (en)
Spanish (es)
Inventor
Yong-Sung Kim
Dong-Ki Choi
Seung-Min Shin
Sung-Hoon Kim
Original Assignee
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orum Therapeutics Inc filed Critical Orum Therapeutics Inc
Priority claimed from PCT/KR2015/007627 external-priority patent/WO2016013871A1/ko
Publication of MX2017001012A publication Critical patent/MX2017001012A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/57575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017001012A 2014-07-22 2015-07-22 Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo. MX2017001012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140092687 2014-07-22
KR1020150103214A KR101602876B1 (ko) 2014-07-22 2015-07-21 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
PCT/KR2015/007627 WO2016013871A1 (ko) 2014-07-22 2015-07-22 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용

Publications (1)

Publication Number Publication Date
MX2017001012A true MX2017001012A (es) 2018-06-19

Family

ID=55354089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001012A MX2017001012A (es) 2014-07-22 2015-07-22 Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo.

Country Status (11)

Country Link
US (1) US10851177B2 (enExample)
EP (1) EP3173099B1 (enExample)
JP (1) JP6798988B2 (enExample)
KR (2) KR101602876B1 (enExample)
CN (1) CN106999575A (enExample)
AU (1) AU2015292956B2 (enExample)
BR (1) BR112017001306A2 (enExample)
CA (1) CA2955265A1 (enExample)
IL (1) IL250137B (enExample)
MX (1) MX2017001012A (enExample)
RU (1) RU2017103679A (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
US11155641B2 (en) * 2016-05-27 2021-10-26 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
KR102163305B1 (ko) 2017-11-16 2020-10-08 오름테라퓨틱 주식회사 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도
WO2019244086A1 (en) 2018-06-21 2019-12-26 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
WO2020022262A1 (en) * 2018-07-23 2020-01-30 Chugai Seiyaku Kabushiki Kaisha Target cell specific cytosol-penetrating antigen-binding molecules
WO2020149613A1 (ko) * 2019-01-15 2020-07-23 오름테라퓨틱 주식회사 세포질 침투성이 증진된 항체
ES3042223T3 (en) * 2019-05-01 2025-11-19 Univ Santiago Compostela Intracellular delivery of anti-kras antibodies formulated into nanocapsules
US20220112308A1 (en) * 2020-04-30 2022-04-14 Genentech, Inc. Kras specific antibodies and uses thereof
WO2022212894A1 (en) * 2021-04-02 2022-10-06 The General Hospital Corporation Methods for inhibiting ras
KR102623211B1 (ko) 2021-07-20 2024-01-11 아주대학교산학협력단 세포 내부에 침투하여 표적단백질을 분해하여 제거하는 세포침투 분해항체 및 이의 용도
US20250122308A1 (en) * 2021-09-17 2025-04-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeting mutant kras with a mutation specific iga

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CN1241574A (zh) 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
CA2506128A1 (en) 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
KR20090008290A (ko) * 2006-03-27 2009-01-21 글로브이뮨 Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법
CN101965406A (zh) 2008-01-03 2011-02-02 斯克里普斯研究院 通过模块识别结构域的抗体靶向
KR100849941B1 (ko) 2008-04-29 2008-08-01 원우이에프엔지니어링주식회사 열 및 연기 화재감지장치 복합시험기
EP2279002B1 (en) 2008-04-30 2013-08-14 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
KR101075123B1 (ko) * 2008-10-24 2011-10-19 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
CN102209726A (zh) 2008-11-11 2011-10-05 亚州大学校产学协力团 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物
CN101402675B (zh) 2008-11-28 2012-05-30 中国人民解放军第三军医大学第三附属医院 一种靶向抑制ανβ3阳性细胞增殖的环肽
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
GB201103631D0 (en) 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
EP2694555B1 (en) 2011-04-01 2019-07-10 Yale University Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
WO2014042209A1 (ja) 2012-09-14 2014-03-20 公益財団法人がん研究会 ＥｐＣＡＭに結合するペプチド
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
WO2016013870A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
JP6903587B2 (ja) 2015-04-03 2021-07-14 ユーリカ セラピューティックス， インコーポレイテッド Ａｆｐペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
KR101790669B1 (ko) 2015-10-14 2017-10-26 아주대학교산학협력단 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도
US11155641B2 (en) 2016-05-27 2021-10-26 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
KR101836392B1 (ko) 2016-08-17 2018-03-08 한림대학교 산학협력단 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물
KR102163305B1 (ko) 2017-11-16 2020-10-08 오름테라퓨틱 주식회사 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도
WO2019244086A1 (en) 2018-06-21 2019-12-26 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies

Also Published As

Publication number Publication date
IL250137A0 (en) 2017-03-30
KR101732553B1 (ko) 2017-05-08
US10851177B2 (en) 2020-12-01
KR20160033670A (ko) 2016-03-28
AU2015292956B2 (en) 2020-04-02
KR101602876B1 (ko) 2016-03-11
EP3173099B1 (en) 2020-03-04
CA2955265A1 (en) 2016-01-28
CN106999575A (zh) 2017-08-01
RU2017103679A (ru) 2018-08-06
US20170158777A1 (en) 2017-06-08
JP2017529870A (ja) 2017-10-12
EP3173099A4 (en) 2018-03-14
KR20160011599A (ko) 2016-02-01
IL250137B (en) 2020-05-31
JP6798988B2 (ja) 2020-12-09
AU2015292956A1 (en) 2017-02-09
BR112017001306A2 (pt) 2018-01-30
EP3173099A1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2017001012A (es) Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo.
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
CY1122953T1 (el) Ενα καινοτομο συμπλοκο που περιλαμβανει ενα κυτταροδιεισδυτικο πεπτιδιο, ενα φορτιο και εναν tlr πεπτιδικο αγωνιστη για την αντιμετωπιση του ορθοκολικου καρκινου
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2020008795A (es) Anti cuerpos anti tigit y usos de los mismos.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
PE20151180A1 (es) Anticuerpos anti-ceacam5 y usos de estos
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
GT201700102A (es) Conjugados de anticuerpo-fármaco
MX2018015353A (es) Usos terapeuticos de un inhibidor de c-raf.
EA201690868A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга
MX377844B (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
ECSP12012194A (es) Proteínas ligando dll4 terapéuticas
MX2016009554A (es) Anticuerpos humanos para pd-1.
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
AR093357A1 (es) Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
MX380358B (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
EA201590085A1 (ru) Антитела анти-egfr и их применение
AR124455A2 (es) Proteínas de unión específicas y sus usos
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака